An oral dual release dose system / dose form is described, which includes an immediate release component / component and a delayed release component / component. If you are already registered, please log in first.It includes dual release of direct release components and delayed release components. Each direct release component / component and delayed release component / component includes one or more doxilinsone of its analogs, one of its derivatives, one of its prodrugs, one of its metabolites and / or its salt and one or several of pyridoxine, its salt, one of its metabolites and / or a salt of the metabolite. The oral dual-release dosing system / dosage form exhibits an improved pharmacokinetic profile compared to the current Diclectin® formulation and is useful, for example, for the relief of nausea and vomiting symptoms, for example, in the case of nausea and vomiting in pregnancy (NVP). Claim 1: An oral dual-release composition comprising (a) one or more of (i) doxylamine, (ii) one of its analogs, (iii) one of its derivatives,(I V) one of its ecologists, (V) one of its metabolites and (VI) any one of (I) - (V) salts；(b) One or more of (I) pyridoxine (II) analogues, (III) one of its derivatives, (I V) one of its derivatives, (V) one of its metabolites, (VI) any of (I) - (V) salts,This oral dual release component includes: (a) a direct release component, including: (a) one or more (I) doxycycline (II) analogues, (III) a derivative, (IV) a by-product, (V) a metabolite, (VI) any (I) salt (V)；And / or (b) one or more of (I) pyridoxine, (II) its analogues, (III) its derivatives, (I V) one of its derivatives, (V) one of its metabolites, (VI) any of (I) - (V) salts；Y (b) delayed release components, including: (a) one or more doxycycline, (I) an analog, (III) a derivative, (I V) a by-product, (V) a metabolite, (VI) any salt (I) - (V)；And / or (b) one or more of (I) pyridoxine, (II) its analogues, (III) its derivatives, (I V) one of its derivatives, (V) one of its metab
